Is finerenone also called Kerendia (finerenone)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is Finerenone Also Called Kerendia?

Yes, finerenone is marketed under the brand name Kerendia®. 1, 2

Drug Identity

  • Finerenone is the generic name for the medication, while Kerendia® is the brand name used commercially 1, 2

  • Kerendia® (finerenone) is a first-in-class, orally administered, selective, nonsteroidal mineralocorticoid receptor antagonist (MRA) developed by Bayer HealthCare Pharmaceuticals 2

FDA Approval and Indication

  • Finerenone/Kerendia® received FDA approval in the United States to reduce the risk of sustained eGFR decline, end-stage renal disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes 2

  • The medication is indicated specifically for adults with type 2 diabetes and chronic kidney disease with albuminuria (ACR ≥30 mg/g) despite maximum tolerated doses of renin-angiotensin system inhibitors, with eGFR ≥25 mL/min/1.73 m² and normal serum potassium 3

Clinical Context

  • Finerenone is classified as a nonsteroidal MRA, distinguishing it from older steroidal MRAs like spironolactone and eplerenone 4

  • The drug provides dual cardiorenal protection, reducing both kidney disease progression (23% reduction in composite kidney outcomes) and cardiovascular events (13% reduction in cardiovascular endpoints) 3, 5

References

Research

Finerenone: First Approval.

Drugs, 2021

Guideline

Finerenone Indication in Adults with Type 2 Diabetes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Finerenone in Chronic Kidney Disease and Type 2 Diabetes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.